Brazil's New Data Maze: Pure Global on Unseen Traps in ANVISA's SaMD Cybersecurity Rules.

In this episode, we dissect the immediate impact of Brazil's new ANVISA resolution, RDC 848/2024. This isn't just another regulatory update; it's a fundamental shift in how Brazil evaluates the safety and performance of medical devices, with a sharp new focus on lifecycle risk management and cybersecurity.

We explore how this change disrupts the conventional market entry strategy for international MedTech companies. A previously straightforward submission process now requires a new level of evidence, particularly for connected devices and Software as a Medical Device (SaMD), creating unforeseen delays and costs for those unprepared.

**Key Questions Answered:**
* Why is Brazil's RDC 848/2024 more than just a standard update?
* What are the new, unwritten cybersecurity requirements ANVISA now expects for SaMD?
* How does this resolution impact your existing FDA or CE-marked technical files?
* Is your current risk management plan now obsolete for the Brazilian market?
* What specific threat modeling is now necessary for connected devices?
* How can you prevent a six-month delay on your product launch in Brazil?
* What are the hidden compliance costs associated with this new regulation?

Navigating these complex changes requires deep local expertise and a proactive strategy. Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI and data tools to streamline global market access. Let us help you turn regulatory hurdles into market opportunities. Contact us at info@pureglobal.com or visit https://pureglobal.com/.